title: Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody.
abstract: Multispecific proteins, such as bispecific antibodies (BsAbs), that bind to two different ligands are becoming increasingly important therapeutic agents. Such BsAbs can exhibit markedly increased target binding and target residence time when both pharmacophores bind simultaneously to their targets. The cross-arm binding efficiency (χ) describes an increase in apparent affinity when a BsAb binds to the second target or receptor (R2) following its binding to the first target or receptor (R1) on the same cell. χ is an intrinsic characteristic of a BsAb mostly related to the binding epitopes on R1 and R2. χ can have significant impacts on the binding to R2 for BsAbs targeting two receptors on the same cell. JNJ-61186372, a BsAb that targets epidermal growth factor receptor (EGFR) and c-Met, was used as the model compound for establishing a method to characterize χ. The χ for JNJ-61186372 was successfully determined via fitting of in vitro cell binding data to a ligand binding model that incorporated χ. The model-derived χ value was used to predict the binding of JNJ-61186372 to individual EGFR and c-Met receptors on tumor cell lines, and the results agreed well with the observed IC50 for EGFR and c-Met phosphorylation inhibition by JNJ-61186372. Consistent with the model, JNJ-61186372 was shown to be more effective than the combination therapy of anti-EGFR and anti-c-Met monovalent antibodies at the same dose level in a mouse xenograft model. Our results showed that χ is an important characteristic of BsAbs, and should be considered for rationale design of BsAbs targeting two membrane bound targets on the same cell.
authors.affiliation: a Biologics Clinical Pharmacology , Janssen R&D US.
authors.forename: Songmao
authors.initials: S
authors.lastname: Zheng
authors.affiliation: c US Biology Oncology , Janssen R&D US.
authors.forename: Sheri
authors.initials: S
authors.lastname: Moores
authors.affiliation: b Biologics Research , Janssen R&D US.
authors.forename: Stephen
authors.initials: S
authors.lastname: Jarantow
authors.affiliation: b Biologics Research , Janssen R&D US.
authors.forename: Jose
authors.initials: J
authors.lastname: Pardinas
authors.affiliation: b Biologics Research , Janssen R&D US.
authors.forename: Mark
authors.initials: M
authors.lastname: Chiu
authors.affiliation: d Quantitative Sciences , Janssen R&D US.
authors.forename: Honghui
authors.initials: H
authors.lastname: Zhou
authors.affiliation: a Biologics Clinical Pharmacology , Janssen R&D US.
authors.forename: Weirong
authors.initials: W
authors.lastname: Wang
mesh_terms: D000818:Animals; D018033:Antibodies, Bispecific / Q000276:immunology / Q000494:pharmacology; D000912:Antibodies, Neoplasm / Q000276:immunology / Q000494:pharmacology; D045744:Cell Line, Tumor; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000276:immunology; D005260:Female; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000276:immunology; D023041:Xenograft Model Antitumor Assays
chemical_list: D018033:Antibodies, Bispecific; D000912:Antibodies, Neoplasm; C512478:EGFR protein, human; D066246:ErbB Receptors; C080835:RON protein; D020794:Receptor Protein-Tyrosine Kinases
keywords: Bispecific antibody; c-Met; cross-arm binding efficiency (χ); epidermal growth factor receptor; mouse xenograft model; pharmacokinetic/pharmacodynamic modeling; quantitative flow cytometry; receptor occupancy